Idorsia Ltd (OTCMKTS:IDRSF) Short Interest Down 27.4% in September

Idorsia Ltd (OTCMKTS:IDRSF) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 975,400 shares, a decrease of 27.4% from the August 31st total of 1,342,900 shares. Based on an average trading volume of 1,100 shares, the days-to-cover ratio is presently 886.7 days. Based on an average trading volume of 1,100 shares, the days-to-cover ratio is presently 886.7 days.

Idorsia Price Performance

IDRSF stock opened at $5.82 on Thursday. Idorsia has a 12-month low of $0.70 and a 12-month high of $5.82. The stock’s 50 day simple moving average is $3.80 and its 200 day simple moving average is $2.51.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a research note on Friday, August 22nd. HC Wainwright upgraded Idorsia from a “neutral” rating to a “buy” rating in a research note on Monday, September 15th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Idorsia has a consensus rating of “Moderate Buy”.

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.